US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Lead asset EVO756 shows promising Phase 2 data in symptomatic dermographism, validating its MRGPRX2-targeting mechanism and supporting further expansion into atopic dermatitis.</li>
<li>A $115M Series C co-led by RA Capital and Sectoral Asset Management strengthens credibility and provides funding for multiple Phase 2 clinical programs.</li>
<li>Evommune’s IPO is multiple-times oversubscribed, driven by significant demand from healthcare-dedicated investors and mutual funds, signaling robust institutional interest.</li>
</ul>


Lead asset EVO756 shows promising Phase 2 data in symptomatic dermographism, validating its MRGPRX2-targeting mechanism and supporting further expansion into atopic dermatitis.
A $115M Series C co-led by RA Capital and Sectoral Asset Management strengthens credibility and provides funding for multiple Phase 2 clinical programs.
Evommune’s IPO is multiple-times oversubscribed, driven by significant demand from healthcare-dedicated investors and mutual funds, signaling robust institutional interest.


Evommune Inc. (EVMN): RA Capital Backed Biotech Tests the IPO Market

<ul>
<li>Exzeo Group (XZO US) is to offer 8 million shares at $20-$22 equating to a valuation of $1.8b-$2.0b and can go public as early as November 5th.</li>
<li>The underwriters have reserved up to 5% of the shares of common stock offered through a directed share program.</li>
<li>This company is a technology arm of HCI and revenue for this company is growing at a very strong pace (80% in 1H 2025). </li>
</ul>


Exzeo Group (XZO US) is to offer 8 million shares at $20-$22 equating to a valuation of $1.8b-$2.0b and can go public as early as November 5th.
The underwriters have reserved up to 5% of the shares of common stock offered through a directed share program.
This company is a technology arm of HCI and revenue for this company is growing at a very strong pace (80% in 1H 2025). 


Exzeo Group, Inc. (XZO): Insurance Technology Platform Sets Terms for IPO; Seeking $2.0b Valuation

BETA Technologies / Equity Capital Markets

<ul>
<li>BETA Technologies (BETA US) is to offer 25.0 million shares at $27-$33 equating to a valuation of $5.9b-$7.2b and can go public as soon as November 4th.</li>
<li>There are a number of anchor order commitments on the cover of the prospectus in addition to a 5% directed share program.</li>
<li>While the company has significant losses, they should be seen in light of its strong potential in low-cost air travel.</li>
</ul>


BETA Technologies (BETA US) is to offer 25.0 million shares at $27-$33 equating to a valuation of $5.9b-$7.2b and can go public as soon as November 4th.
There are a number of anchor order commitments on the cover of the prospectus in addition to a 5% directed share program.
While the company has significant losses, they should be seen in light of its strong potential in low-cost air travel.


BETA Technologies (BETA): Electric Aircraft Maker Sets Wide Range, Seeking up to $7.2b Valuation

<ul>
<li>Navan is offering 36.9mm shares at $24-$26 and will debut on October 31st invoking a 20-day effectiveness rule during the current government shutdown.</li>
<li>Their revenue grew 33% year-over-year from $402 million in fiscal 2024 to $537 million in fiscal 2025.</li>
<li>Navan (formerly TripActions) is led by two high-profile co-founders who previously sold had a business acquired in this space.</li>
</ul>


Navan is offering 36.9mm shares at $24-$26 and will debut on October 31st invoking a 20-day effectiveness rule during the current government shutdown.
Their revenue grew 33% year-over-year from $402 million in fiscal 2024 to $537 million in fiscal 2025.
Navan (formerly TripActions) is led by two high-profile co-founders who previously sold had a business acquired in this space.


Navan Inc. (NAVN):AI-Powered Booking System Pushes Ahead with IPO Amidst Government Shutdown

MapLight Therapeutics / Equity Capital Markets

<ul>
<li>Maplight Therapeutics set terms for its IPO and can debut on the Nasdaq as early as October 27th. </li>
<li>Maplight is offering 17.25 million shares at $17.00 with the lead underwriters on the transaction being Morgan Stanley, Jefferies, Leerink and Stifel. </li>
<li>The company’s decision to wait through the 20-day effectiveness period amid the government shutdown underscores both patience and confidence in its investor base.</li>
</ul>


Maplight Therapeutics set terms for its IPO and can debut on the Nasdaq as early as October 27th. 
Maplight is offering 17.25 million shares at $17.00 with the lead underwriters on the transaction being Morgan Stanley, Jefferies, Leerink and Stifel. 
The company’s decision to wait through the 20-day effectiveness period amid the government shutdown underscores both patience and confidence in its investor base.


Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

United States

MapLight Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on improving the lives of patients suffering from debilitating central nervous system disorders. MapLight Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MapLight Therapeutics (MPLT US)

Evommune Inc. (EVMN): RA Capital Backed Biotech Tests the IPO Market

Phase 2 data for EVO756 in dermographism leads to successful $115M Series C funding and oversubscribed IPO for Evommune, signaling strong...

IPO Boutique

Exzeo Group, Inc. (XZO): Insurance Technology Platform Sets Terms for IPO; Seeking $2.0b Valuation

Exzeo Group plans to go public with 8 million shares at $20-$22, valued at $1.8b-$2.0b, with strong revenue growth of 80% in 1H 2025. Directed...

IPO Boutique

BETA Technologies (BETA): Electric Aircraft Maker Sets Wide Range, Seeking up to $7.2b Valuation

BETA Technologies plans to go public with 25 million shares valued at $5.9b-$7.2b, despite significant losses, highlighting potential in low-cost...

IPO Boutique

Navan Inc. (NAVN):AI-Powered Booking System Pushes Ahead with IPO Amidst Government Shutdown

Navan to debut on Oct 31 with 36.9mm shares at $24-$26, despite government shutdown. Led by co-founders with successful track record in the...

IPO Boutique

Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

Maplight Therapeutics sets IPO terms, offering 17.25 million shares at $17.00 with debut on Nasdaq possible by October 27th, showing patience and...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Evommune Inc. (EVMN): RA Capital Backed Biotech Tests the IPO Market

Phase 2 data for EVO756 in dermographism leads to successful $115M Series C funding and oversubscribed IPO for Evommune, signaling strong...

IPO Boutique

Exzeo Group, Inc. (XZO): Insurance Technology Platform Sets Terms for IPO; Seeking $2.0b Valuation

​Exzeo Group plans to go public with 8 million shares at $20-$22, valued at $1.8b-$2.0b, with strong revenue growth of 80% in 1H 2025. Directed...

IPO Boutique

BETA Technologies (BETA): Electric Aircraft Maker Sets Wide Range, Seeking up to $7.2b Valuation

​BETA Technologies plans to go public with 25 million shares valued at $5.9b-$7.2b, despite significant losses, highlighting potential in low-cost...

IPO Boutique

Navan Inc. (NAVN):AI-Powered Booking System Pushes Ahead with IPO Amidst Government Shutdown

​Navan to debut on Oct 31 with 36.9mm shares at $24-$26, despite government shutdown. Led by co-founders with successful track record in the...

IPO Boutique

Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

​Maplight Therapeutics sets IPO terms, offering 17.25 million shares at $17.00 with debut on Nasdaq possible by October 27th, showing patience and...

IPO Boutique

Exzeo Group plans to go public with 8 million shares at $20-$22, valued at $1.8b-$2.0b, with strong revenue growth of 80% in 1H 2025. Directed...

BETA Technologies plans to go public with 25 million shares valued at $5.9b-$7.2b, despite significant losses, highlighting potential in low-cost...

Navan to debut on Oct 31 with 36.9mm shares at $24-$26, despite government shutdown. Led by co-founders with successful track record in the...

Maplight Therapeutics sets IPO terms, offering 17.25 million shares at $17.00 with debut on Nasdaq possible by October 27th, showing patience and...